Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue — related party | $1,154 | $1,115 | $2,010 | $2,569 |
| Operating expenses: | ||||
| Research and development | 33,397 | 41,375 | 67,502 | 81,937 |
| General and administrative | 11,042 | 13,117 | 28,447 | 26,401 |
| Total operating expenses | 44,439 | 54,492 | 95,949 | 108,338 |
| Loss from operations | (43,285) | (53,377) | (93,939) | (105,769) |
| Other income: | ||||
| Interest income | 788 | 743 | 1,809 | 1,925 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's G&A?
- Prime Medicine (PRME) reported G&A of $11.04M in Q2 2026.
- How has Prime Medicine's G&A changed year-over-year?
- Prime Medicine's G&A decreased by 15.8% year-over-year, from $13.12M to $11.04M.
- What is the long-term trend for Prime Medicine's G&A?
- Over 3 years (2022 to 2025), Prime Medicine's G&A has grown at a 20.6% compound annual growth rate (CAGR), from $29.82M to $52.35M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Prime Medicine's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude